Welcome to our dedicated page for PaxMedica SEC filings (Ticker: PXMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PaxMedica's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PaxMedica's regulatory disclosures and financial reporting.
Kuvatris Therapeutics, Inc. (formerly PaxMedica) reports a much smaller net loss but severe financial strain for the quarter ended September 30, 2024. The company posted a net loss of $0.9 million for the quarter and $7.6 million for the nine months, compared with losses of $5.0 million and $12.4 million in the prior-year periods, mainly because general and administrative and research and development expenses were sharply reduced.
Cash fell to $444,855 from $4.7 million at December 31, 2023, leaving total assets of $0.8 million against liabilities of $2.8 million and a stockholders’ deficit of $(1.9) million. The filing states there is substantial doubt about the company’s ability to continue as a going concern.
Subsequent events radically changed the capital structure. In February 2025, the company issued 114,754,700 common shares to Pax Rescue Vehicle, LLC for $10,000 plus legal fees, giving PRV over 90% of voting power and effecting a change in control as part of a going-private strategy. The company then declared DTC‑held common shares null and void, directed its transfer agent to cancel those shares, and filed a Form 15 to terminate Exchange Act registration.